FAQ: Branded Legacy, Inc. (OTC: BLEG) Acquisition of Bio Legacy Evaluative Group

What is the significance of Branded Legacy’s acquisition of Bio Legacy Evaluative Group?

This acquisition allows Branded Legacy to expand into the biotech and medical devices sector, addressing critical global health issues such as the addiction epidemic and vaccine distribution inefficiencies.

How was the acquisition of Bio Legacy Evaluative Group by Branded Legacy structured?

The acquisition was an all-stock deal valued at $1.5 million in Preferred D shares, including performance-based conversion milestones, a two-year lock-up, and a $1 million R&D commitment post-uplisting to OTCQB.

What does Bio Legacy Evaluative Group bring to Branded Legacy?

Bio Legacy brings a patented all-in-one intranasal naloxone device targeting a rapidly growing market and technology for nasal delivery of vaccines and cold-chain therapies.

When was the acquisition of Bio Legacy Evaluative Group by Branded Legacy completed?

The transaction was closed on July 31, 2025.

What are the projected market growth figures for the intranasal naloxone device?

The market for the intranasal naloxone device is projected to grow from $371 million in 2022 to over $1.16 billion by 2032.

Who is the CEO of Bio Legacy Evaluative Group?

Amin Janmohamed is the CEO of Bio Legacy Evaluative Group.

Where can I find more information about Branded Legacy, Inc.?

For more information, visit the company’s website at https://BrandedLegacy.com.

What is the focus of Branded Legacy, Inc.?

Branded Legacy specializes in the development and commercialization of biotech and wellness products, focusing on strategic growth, innovation, and quality.

How can I view the full press release about the acquisition?

The full press release can be viewed at https://ibn.fm/U7eSy.